2-aryl benzimidazoles as PPARGC1A activators for treatment of neurodegenerative diseases
By developing 2-arylbenzimidazole and other compounds that can activate Ppargc1a, the problem of lack of effective methods for treating neurodegenerative diseases has been solved, and amyotrophic lateral sclerosis, Alzheimer's disease, etc. Potential treatment of the disease delays the death of neuronal cells.
Patent Information
- Application Number
- CN202411199938.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-06
- Filing Date
- 2019-08-06
- Publication Date
- 2024-11-29
AI Technical Summary
The existing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. lack effective treatments, and the specific signaling pathways leading to neuronal cell death have not yet been found. Completely understand.
Compounds such as 2-arylbenzimidazole, 2-arylbenzooxazole, 2-arylbenzothiazole and 2-arylimidazole[1,2-a]pyridine and their prodrug derivatives have been developed. It can activate Ppargc1a and thus be used to treat the above-mentioned neurodegenerative diseases.
By activating Ppargc1a, these compounds may inhibit the inflammatory response of bone marrow cells, slow down neuronal cell death and delay disease progression, providing new treatments for neurodegenerative diseases.
Smart Images

Figure CN119033775A_ABST
Abstract
Description
This case is a divisional application. The parent case of the divisional application is an invention patent application with an application date of August 6, 2019, application number 201980065941.4, and invention name “2-arylbenzimidazoles as PPARGC1A activators for the treatment of neurodegenerative diseases”, the full text of which is incorporated into this application by reference. Technical Field
[0001] The present application relates to the use of 2-arylbenzimidazole, 2-arylbenzoxazole, 2-arylbenzothiazole, 2-arylimidazo[1,2-a]pyridine and their prodrug derivatives as chemical activators of Ppargc1a for treating neurodegenerative diseases. Background Art Amyotrophic lateral sclerosis
[0002] Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons, leading to a progressive decline in motor function and ultimately death. The motor symptoms of ALS include muscle weakness, convulsions, and weight loss, which in turn lead to difficulty speaking, swallowing, and breathing. The cause of motor neuron death in ALS is unknown, and 5-10% of ALS cases are inherited.
[0003] Activation of immune cells in the central and peripheral nervous systems has been proposed to be a key determinant of disease progression in ALS (Phani et al., Front Pharmacol, 3:150, 2012). Specifically, microglia and macrophages have been shown to play different roles in the neuroinflammation component of the disease (Dibaj et al., PLoS One, 6(3):el7910, 2011; Boillee et al., Science, 312:1389-92, 2006). Notably, bone marrow transplantation (BMT) has been shown to prolong survival in animal models of ALS by replacing host myeloid cells, which is thought to be mediated by replacing CNS microglia (Beers et al., Proc Natl Acad Sci US A. 103:16021-6, 2006). However, recent studies have shown that these cells do not develop from bone marrow cells, but rather from more primitive yolk sac progenitor cells (Ginhoux et al., Science, 330:841-5, 2110), indicating that the bone marrow-derived cells mediating the therapeutic effects of BMT in the above studies are more likely peripheral or perivascular macrophages. However, the specific signaling pathways that lead to innate immune cell-mediated inflammation in ALS are still not fully understood.
[0004] Currently, there is no cure for ALS. Certain therapies, such as riluzole, bone marrow transplantation (Deda, Cytotherapy, 11: 18-25, 2009) and non-invasive ventilation (McDeRmott et al., BMJ, 336: 658-62, 2008) have shown some effect in improving quality of life and prolonging survival, but no therapy can cure or provide significant benefit. Alzheimer's disease
[0005] Alzheimer's disease (AD) is a degenerative brain disease characterized clinically by the progressive loss of motor function, accompanied by loss of memory, cognition, reasoning, judgment, and emotional stability, gradually leading to severe neurodegeneration and ultimately death. Neuronal metabolic dysfunction in the form of oxidative stress has been proposed to be the root cause of neurodegeneration in AD (Friedland-Leuner et al., Mol Biol Transl Sci, 127: 183-201, 2014).
[0006] Although AD develops differently for each individual, there are many common symptoms. Early symptoms are often mistakenly thought to be age-related problems or manifestations of stress. In the early stages, the most common symptoms are decreased motor skills and difficulty remembering recent events, which is called short-term memory loss (Buchman et al., Exp Rev Neurother, 11: 665-76, 2011). When AD is suspected, the diagnosis is usually based on tests that assess behavior and thinking skills, and if possible, a brain scan is usually performed. However, a brain tissue examination is required to confirm the diagnosis. As the disease progresses, symptoms may include confusion, irritability, aggression, mood swings, language disorders, and long-term memory loss. As the individual's condition worsens, he / she will often avoid family and society. Then, the body's functions are gradually lost, eventually leading to death. Parkinson's disease
[0007] Parkinson's disease (PD), also called idiopathic or primary Parkinson's disease, is a degenerative neurological disorder of the central nervous system. The motor symptoms of PD are caused by the death of dopamine-producing cells in the substantia nigra, a region of the midbrain, for reasons that are not yet understood. Early in the disease, the most obvious symptoms are movement-related. These include tremors, rigidity, slowness of movement and difficulty with fine motor movements, trouble walking and gait abnormalities. Later, problems with thinking and behavior may develop, with dementia usually occurring in the later stages of the disease, and depression being the most common psychiatric symptom. Other symptoms include sensory, sleep and mood problems.
[0008] PD is characterized by progressive motor impairment and neuroinflammation caused by microglia, which are innate immune cells of the central nervous system (Aguzzi et al., Science, 339: 156-61, 2013). Inflammatory mediators produced by dysfunctional microglia have been shown to cause neuronal cell death, which is the basis for the progressive impairment of cognitive and behavioral performance in neurodegenerative diseases (Czirr et al., J Clin Invest, 122: 1156-63, 2012). However, the specific signaling pathways that lead to microglia-mediated inflammation remain elusive. Huntington's disease
[0009] Huntington's disease (HD) is an autosomal dominant degenerative disorder of the central nervous system in which the Huntington gene is mutated. HD is an inherited disorder that causes the progressive failure (degeneration) of nerve cells in the brain. HD has a wide range of effects on a person's functional ability, often resulting in movement, thinking (cognition), and psychiatric impairments.
[0010] Symptoms of HD vary from patient to patient, however, the progression of the disease is relatively predictable (Mason S et al., J Neurol, 2015). In the early stages of the disease, symptoms are mild, such as mood changes. Later, cognitive and motor problems may develop, and dementia usually occurs in the late stages of the disease. Chorea (involuntary movements) is the most common motor symptom. Other complications include pneumonia, heart disease, and physical injuries from falls.
[0011] There is currently no cure for HD, and patients with advanced disease require full-time care. Frontotemporal lobar degeneration
[0012] Frontotemporal lobar degeneration (FTD) is a disease closely related to AD, the progressive degeneration of which occurs in the frontal and temporal lobes of the brain. Gliosis and inflammatory activation of microglia have been documented in human and animal FTD models (Cagnin et al. Annals of Neurol, 2004 6:894-897; Yi et al. J. Exp. Med, 2010.1:117-128). The behavior and language abilities of FTD patients gradually decline, while memory is usually relatively preserved. As the disease progresses, it becomes increasingly difficult for patients to carry out activities, behave appropriately, and take care of themselves. There is currently no treatment to slow or prevent the progression of the disease. Lewy body dementia
[0013] Dementia with Lewy bodies (DLB) is a type of dementia associated with PD. The hallmark of this disease is the presence of alpha-synuclein aggregates in the patient's brain. These patients experience PD-like symptoms, including hunchback, muscle stiffness, twisted gait, and difficulty moving, as well as changes in reason and thinking, and memory loss (but not as obvious as AD). Since Lewy bodies are also present in PD, the two diseases may be associated with the same underlying abnormalities in the way the brain processes the protein alpha-synuclein. In addition, similar to PD, microglia-associated neuroinflammation is also present in the brains of DLB patients, although this pathological feature occurs more extensively (Iannaccone et al., Parkinsonism Relat. Disord, 2013 19: 47-52). Motor neurone disease
[0014] Motor neuron disease (MND) is a neurological disease similar to ALS that selectively affects motor neurons, which are cells that control voluntary muscle activity (including speaking, walking, swallowing and motor activity). There is currently no effective treatment for MND. They are essentially neurodegenerative and lead to progressive disability and death. In addition, in animal models of MND, a specific pathway called progranulin can trigger inflammatory activation of microglia, and genetic ablation of this pathway can delay disease progression (Philips et al., J Neuropathol Exp Neurol, 2010 69: 1191-200). Demyelinating diseases
[0015] Demyelinating diseases, such as Guillain-Barré syndrome and multiple sclerosis (MS), are degenerative diseases in which the myelin sheath of neurons is damaged. This damage impairs the signaling of the affected nerves, leading to sensory, motor, cognitive or other functional deficiencies, and these diseases are incurable. Its best-known form is MS, a disease involving a subset of cells of the immune system. For example, persistent demyelination is often associated with infiltration of circulating T cells and macrophages and inflammatory activation of microglia (Kutzelnigg et al., Handb. Clin. Neurol, 2014, 122: 15-58).
[0016] The compounds described herein can activate Ppargc1a and can be used to treat the above-mentioned neurodegenerative diseases. Summary of the invention
[0017] 2-Arylbenzimidazoles, 2-arylbenzoxazoles, 2-arylbenzothiazoles, and 2-arylimidazo[1,2-a]pyridines have been found to activate Ppargc1a. These compounds and their prodrug derivatives are useful for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal lobar degeneration, Lewy body dementia, motor neuron disease, and demyelinating diseases.
[0018] In the first aspect, the present application relates to a compound represented by the following formula (I): in: W 2 Is N or CR 2 ; W 3 Is N or CR 3 ; W 4 Is N or CR 4 ; W 5 Is N or CR 5 ; W 6 Is N or CR 6 ; W 7 Is N or CR 7 ; W 8 Is N or CR 8 ; R 1 Selected from -CH2OC(=O)R 30 、-CH2OP(=O)OR 40 OR 41 、-C(=O)OR 42 and -C(=O)R 43 ; in: R 30 Selected from (C1-C 10 ) alkyl, amino-substituted (C1-C 10 ) hydrocarbon group, (C1-C4) alkoxycarbonyl substituted (C1-C 10 ) alkyl, carboxyl-substituted (C1-C 10 )alkyl, carboxyl, (C1-C6)alkoxycarbonyl, (C1-C6) alkoxycarbonylamino, methylthio, heterocyclic, (C1-C 10 ) Oxyalkyl, CHR 44 NHR 45 and guanidine; in: R 44 selected from any naturally occurring amino acid side chains; and R 45 is selected from H, methyl and (C1-C4)alkoxycarbonyl; and R 40 and R 41 independently selected from hydrogen and (C1-C6)alkyl; R 42 is (C1-C5)alkyl; and R 43 is (C1-C3)alkyl; and R 2 , R 3 , R 4 and R 5 independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], carboxamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido; R 6 and R 10 independently selected from hydrogen, deuterium, halogen, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy and amino; R 7 and R 9 are independently selected from hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, and halo(C1-C4)alkoxy; and R 8 Selected from hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy and amino.
[0019] In a second aspect, the present application relates to a compound represented by the following formula (II): in: Ar is W 1 Selected from O, S and NR 1 , or when W 9 When N is 1 Can also be CR 50 ; W 2 Is N or CR 2 ; W 3 Is N or CR 3 ; W 4 Is N or CR 4 ; W 5 Is N or CR 5 ; W 9 is C, or when W 1 Yes CR 50 When; W 9 It can be N; in: R 1 Selected from H, (C1-C3) alkyl, -CH2OC(=O)R 30 、-CH2OP(=O)OR 40 OR 41 、-C(=O)OR 42 and -C(=O)R 43 ; in: R 30 Selected from (C1-C 10 ) alkyl, amino-substituted (C1-C 10 ) hydrocarbon group, (C1-C4) alkoxycarbonyl substituted (C1-C 10 ) alkyl, carboxyl-substituted (C1-C 10 )alkyl, carboxyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonylamino, methylthio, heterocyclic, (C1-C 10 ) Oxyalkyl, CHR 44 NHR 45 and guanidine; in: R 44 selected from any naturally occurring amino acid side chains; and R 45 is selected from H, methyl and (C1-C4)alkoxycarbonyl; and R 40 and R 41 independently selected from hydrogen and (C1-C6)alkyl; R 42 is (C1-C5)alkyl; and R 43 is (C1-C3)alkyl; and R 50 is H or (C1-C3)alkyl; and R 2 , R 3 , R 4 and R 5 independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], carboxamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido; The condition is that only if: W 9 It is C; W 1 YesNR 1 ;and R 1 When it is not H or (C1-C3) alkyl, Ar includes
[0020] In a third aspect, the present application relates to a method for treating a neurodegenerative disease, comprising administering a compound represented by the following formula (III): in: W 1 Selected from O, S and NR 1 , or when W 9 When N is 1 Can also be CR 50 ; W 2 Is N or CR 2 ; W 3 Is N or CR 3 ; W 4 Is N or CR 4 ; W5 Is N or CR 5 ; W 6 Is N or CR 6 ; W 7 N or CR 7 ; W 8 Is N or CR 8 ; W 9 is C, or when W 1 Yes CR 50 When; W 9 It can be N; in: R 1 Selected from H, (C1-C3) alkyl, -CH2OC(=O)R 30 、-CH2OP(=O)OR 40 OR 41 , -C(=O)OR 42 and -C(=O)R 43 ; in: R 30 Selected from (C1-C 10 ) alkyl, amino-substituted (C1-C 10 ) hydrocarbon group, (C1-C 10 ) alkoxycarbonyl substituted (C1-C 10 ) alkyl, carboxyl-substituted (C1-C 10 ) alkyl, carboxyl, (C1-C 10 )alkoxycarbonyl, (C1-C6)alkoxycarbonylamino, methylthio, heterocyclic, (C1-C 10 ) alkoxy, CHR 44 NHR 45 and guanidine; in: R 44 selected from any naturally occurring amino acid side chains; and R 45 is selected from H, methyl and (C1-C4)alkoxycarbonyl; and R 40 and R 41 independently selected from hydrogen and (C1-C6)alkyl; R 42 is (C1-C5)alkyl; and R 43 is (C1-C3)alkyl; and R 50is H or (C1-C3)alkyl; R 2 , R 3 , R 4 and R 5 independently selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], carboxamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido; R 6 and R 10 independently selected from hydrogen, deuterium, halogen, (C1-C3)alkyl, perfluoro(C1-C3)alkyl, hydroxy, (C1-C3)alkoxy, perfluoro(C1-C3)alkoxy and amino; R 7 and R 9 are independently selected from hydrogen, deuterium, hydroxy, cyano, amino, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, and halo(C1-C4)alkoxy; and R 8 is selected from the group consisting of hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy and amino; The condition is that, when the following conditions are met, R 8 Not hydrogen or (C1-C4) alkyl: (a)W 1 YesNR 1 ; (b)R 1 It is hydrogen; (c)W 2 , W 3 , W 4 , W 5 , W 6 and W 7 It is CH; (d)W 8 Yes CR 8 ; (e)W 9 is C; and (f)R 9 and R 10 It's hydrogen.
[0021] In the fourth aspect, the present application relates to a compound as shown in the above-mentioned formula I, II or III or a pharmaceutical composition comprising a compound as shown in the above-mentioned formula I, II or III in medicine and its method and use, particularly for the treatment of neurodegenerative diseases. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal lobar degeneration, Lewy body dementia, motor neuron disease and demyelinating disease. The method includes administering an effective amount of a compound or pharmaceutical composition as described herein.
[0022] In a fifth aspect, the present application relates to methods and uses of compounds as shown in the above formula I, II or III, or pharmaceutical compositions comprising compounds as shown in the above formula I, II or III in medicine, particularly for treating cognitive impairment and neuroinflammation associated with aging in patients. These methods include administering to the patient a pharmaceutical composition of a therapeutically effective amount of a compound as described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Plasma API levels are shown for prodrug examples 6-P, 8-P and 11-P.
[0024] Figure 2 Brain tissue API levels are shown for prodrug examples 6-P, 8-P, and 11-P.
[0025] Figure 3 Liver API levels are shown for prodrug examples 6-P, 8-P, and 11-P. DETAILED DESCRIPTION
[0026] Substituents are generally defined upon introduction and retain that definition throughout the specification and any independent claims.
[0027] In the first composition aspect, the present application relates to a compound represented by the following formula (I) as described herein:
[0028] In the second composition aspect, the present application relates to a compound represented by the following formula (II) as described herein:
[0029] In terms of methods, the present application relates to a compound represented by the following formula (III) as described herein:
[0030] In the examples described below, unless otherwise specified, the compound may be a compound represented by Formula I, II or III.
[0031] In some embodiments of Formula II and III, W 1 YesNR 1 In other embodiments of Formula II and III, W 1 Is O. In other embodiments of Formula II and III, W 1 Is S. In some other embodiments of formula II and III, preferably, when W 9 When N is 1 Yes CR 50 In W 1 Yes CR 50 In some embodiments, R 50 It is H. In W 1 Yes CR 50 In other embodiments, R 50 It is a (C1-C3) alkyl group.
[0032] In some embodiments of Formulas I, II, and III, R 1 is -CH2OC(=O)R 30 ; where R 30 Selected from (C1-C 10 ) alkyl, amino-substituted (C1-C 10 ) hydrocarbon group, (C1-C4) alkoxycarbonyl substituted (C1-C 10 ) alkyl, carboxyl-substituted (C1-C 10 )alkyl, carboxyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonylamino, methylthio, heterocyclic, (C1-C 10 ) oxaalkyl and guanidinyl.
[0033] In some embodiments, when R 1 is -CH2OC(=O)R 30 When R 30 Selected from: (a) (C1-C6) alkyl; (b) phenyl substituted by (C1-C4) alkylamino; (c) decarboxyl residue of natural amino acid; (d) (C1-C3) hydrocarbon substituted by carboxyl; (e) (C1-C5) oxaalkyl; and (d) pyridyl.
[0034] In some embodiments of Formula II and III, R 1 is H. In other embodiments of Formula II and III, R 1 It is a (C1-C3) alkyl group.
[0035] In some embodiments of Formulas I, II and III, W 2is N. In other embodiments of Formulas I, II and III, W 2 Yes CR 2 In some embodiments, W 2 is selected from the group consisting of CH, CF, CD, C-CF3, C-CH3, C-Cl, C-Br, C-OH, C-OCH3, C-NH2, C-CF2H, C-OCF3, C-OCF2H, C-CD3 and C-CONH2. In some embodiments, W 2 Selected from CH, CF, CD, C-CF2H, C-CD3 and C-CF3.
[0036] In W 2 Yes CR 2 In the embodiment, R 2 is selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], formamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido.
[0037] In W 2 Yes CR 2 In some embodiments, R 2 is selected from hydrogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, amino, hydroxy, nitrile, halogen, or carboxamide. In some embodiments, R 2 is selected from hydrogen, trifluoromethyl, methyl, ethyl, methoxy, trifluoromethoxy, amino, hydroxy, nitrile, halogen, or carboxamide. 2 Selected from hydrogen, halogen and perfluoro(C1-C3)alkyl.
[0038] In some embodiments of Formulas I, II and III, W 3 is N. In other embodiments of Formulas I, II and III, W 3 Yes CR 3 In some embodiments, W 3is selected from the group consisting of N, CH, C-NH2, CF, C-CF3, CD, C-OCH3, C-CN, C-OH, C-Cl, C-CH3, C-CF2H, C-OCF3, C-OCF2H, C-CD3 and C-Br. In some embodiments, W 3 Selected from N, CH, C-NH2, CF, C-CF3, C-CF2H, C-CD3 and CD.
[0039] In W 3 Yes CR 3 In some embodiments, R 3 is selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], formamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido.
[0040] In W 3 Yes CR 3 In some embodiments, R 3 is selected from hydrogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, amino, hydroxy, nitrile, halogen or formamide. 3 Yes CR 3 In some embodiments, R 3 is selected from hydrogen, trifluoromethyl, methyl, ethyl, methoxy, trifluoromethoxy, amino, hydroxy, nitrile, halogen or formamide. 3 Yes CR 3 In some embodiments, R 3 Selected from H, halogen and perfluoro(C1-C3)alkyl.
[0041] In some embodiments of Formulas I, II and III, W 4 is N. In other embodiments of Formulas I, II and III, W 4 Yes CR 4 In some embodiments, W 4is selected from the group consisting of N, CH, C-NH2, CF, C-CF3, CD, C-OCH3, C-CN, C-OH, C-Cl, C-CH3, C-CF2H, C-OCF3, C-OCF2H, C-CD3 and C-Br. In some embodiments, W 4 Selected from N, CH, C-NH2, CF, C-CF3, C-CF2H, C-CD3 and CD.
[0042] In W 4 Yes CR 4 In some embodiments, R 4 is selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], formamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido.
[0043] In W 4 Yes CR 4 In some embodiments, R 4 is selected from hydrogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, amino, hydroxy, nitrile, halogen or formamide. 4 Yes CR 4 In some embodiments, R 4 is selected from hydrogen, trifluoromethyl, methyl, ethyl, methoxy, trifluoromethoxy, amino, hydroxy, nitrile, halogen or formamide. 4 Yes CR 4 In some embodiments, R 4 Selected from H, halogen and perfluoro(C1-C3)alkyl.
[0044] In some embodiments of Formulas I, II and III, W 5 is N. In other embodiments of Formulas I, II and III, W 5 Yes CR 5 In some embodiments, W 5is selected from the group consisting of CH, CF, CD, C-CF3, C-CH3, C-Cl, C-Br, C-OH, C-OCH3, C-NH2, C-CF2H, C-OCF3, C-OCF2H, C-CD3 and C-CONH2. In some embodiments, W 5 Selected from CH, CF, CD, C-CF2H, C-CD3 and C-CF3.
[0045] In W 5 Yes CR 5 In the embodiment, R 5 is selected from hydrogen, deuterium, halogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, (C1-C4)acyl, (C1-C4)alkoxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, hydroxy, carboxyl, (C1-C4)alkoxycarbonylamino [—HNC(═O)O-alkyl], formamido [—C(═O)NH2], (C1-C4)alkylaminocarbonyl [—C(═O)NH-alkyl], cyano, acetoxy, nitro, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, mercapto, (C1-C4)alkylthio, aminosulfonyl, (C1-C4)alkylsulfonyl and (C1-C4)amido.
[0046] In W 5 Yes CR 5 In some embodiments, R 5 is selected from hydrogen, perfluoro(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, amino, hydroxy, nitrile, halogen, or carboxamide. In some embodiments, R 5 is selected from hydrogen, trifluoromethyl, methyl, ethyl, methoxy, trifluoromethoxy, amino, hydroxy, nitrile, halogen, or carboxamide. 5 Selected from hydrogen, halogen and perfluoro(C1-C3)alkyl.
[0047] In some embodiments of Formulas I and III, W 6 is N. In other embodiments of Formulas I and III, W 6 Yes CR 6 , preferably CH.
[0048] In W 6 Yes CR 6 In some embodiments, R 6 Selected from hydrogen, deuterium, halogen, (C1-C3) alkyl, perfluoro(C1-C3) alkyl, hydroxy, (C1-C3) alkoxy, perfluoro(C1-C3) alkoxy and amino.
[0049] In some embodiments of Formulas I and III, W 7 is N. In other embodiments of Formulas I and III, W 7 Yes CR 7 In W 7 Yes CR 7 In some embodiments, R 7 is selected from the group consisting of hydrogen, deuterium, hydroxyl, cyano, amino, halogen, halogen(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy and halogen(C1-C4)alkoxy. 7 Yes CR 7 In some embodiments, R 7 It is hydrogen or (C3-C4) alkyl.
[0050] In some embodiments of Formulas I and III, W 8 is N. In other embodiments of Formulas I and III, W 8 Yes CR 8 In W 8 Yes CR 8 In some embodiments, R 8 is selected from hydrogen, deuterium, halogen, halo(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, phenoxy, benzyloxy and amino. 8 Yes CR 8 In some embodiments, R 8 is selected from the group consisting of H, (C1-C4) alkyl, amino, (C1-C4) alkoxy, halo (C1-C4) alkoxy and hydroxy. 8 Yes CR 8 In some embodiments, R 8 is selected from H, tert-butyl, amino and methoxy, when W 7 N or R 7 When it is hydrogen, R 8 Preferred is tert-butyl.
[0051] In some embodiments of Formula II and III, when W 1 Yes CR 50 When W 9 is N. In other embodiments of Formula II and III, when W 1 YesNR 1 , O or S, W 9 It is C.
[0052] In some embodiments of Formulas I and III, R 9is selected from hydrogen, deuterium, hydroxyl, cyano, amino, halogen, halo (C1-C4) alkyl, (C1-C4) alkyl, (C1-C4) alkoxy and halo (C1-C4) alkoxy. In a preferred embodiment, when R 7 is hydrogen and R 8 When H is 9 It is tert-butyl.
[0053] In some embodiments of Formulas I and III, R 10 Selected from hydrogen, deuterium, halogen, (C1-C3) alkyl, perfluoro(C1-C3) alkyl, hydroxy, (C1-C3) alkoxy, perfluoro(C1-C3) alkoxy and amino, preferably H.
[0054] In some embodiments of Formula II, Ar is In other embodiments of Formula II, Ar is In other embodiments of Formula II, Ar is In other embodiments of Formula II, Ar is In other embodiments of Formula II, Ar is
[0055] Upon examination, it will be found that some classes and genera are not patentable to the inventor of this application. In this case, the exclusion of these classes and genera in the applicant's declaration is to meet the requirements of patent examination and does not reflect the inventor's conception or description of his invention, including all members of Genus I, Genus II and Genus III that are not owned by the public.
[0056] As used herein, and as will be understood by those skilled in the art, the term "compound" is intended to include salts of the compound unless expressly further limited. In a specific embodiment, the term "compound of formula" refers to the compound or a pharmaceutically acceptable salt thereof.
[0057] The term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or non-toxic base (including inorganic acids and inorganic bases and organic acids and organic bases). When the compound of the present application is basic, the salt can be prepared from a pharmaceutically acceptable non-toxic acid (including inorganic acids and organic acids). Suitable pharmaceutically acceptable acid addition salts for the compounds of the present application include acetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid (benzenesulfonate), benzoic acid, boric acid, butyric acid, camphoric acid, camphorsulfonic acid, carbonic acid, citric acid, ethanedisulfonic acid, ethanesulfonic acid, ethylenediaminetetraacetic acid, formic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, lactobionic acid, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalenesulfonic acid, nitric acid, oleic acid, pamoic acid, pantothenic acid, phosphoric acid, trimethylacetic acid, polygalacturonic acid, salicylic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, teoclatic acid, p-toluenesulfonic acid, and the like. When the compound contains an acidic side chain, pharmaceutically acceptable base addition salts suitable for the compounds of the present application include, but are not limited to, metal salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, arginine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Where appropriate, further, pharmaceutically acceptable salts include non-toxic ammonium cations and carboxylates, sulfonates and phosphonates attached to alkyl groups having 1 to 20 carbon atoms.
[0058] Although the compounds of formula I, II and III may be administered as raw chemicals, it is preferred that they are present as pharmaceutical compositions. According to another aspect, the present application provides a pharmaceutical composition comprising a compound of formula I or formula II or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients. The carrier must be "acceptable", i.e., compatible with the other ingredients of the formulation and harmless to its recipient.
[0059] Preparations include preparations suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including skin, buccal, sublingual and intraocular) administration. The most suitable approach depends on the condition and disease of the recipient. The preparation can be conveniently provided in unit dosage form and can be prepared by any method known to the pharmaceutical field. All methods include the step of combining a compound of formula I, II or III or a pharmaceutically acceptable salt thereof ("active ingredient") with a carrier constituting one or more auxiliary components. Typically, the active ingredient is uniformly and closely combined with a liquid carrier or a subdivided solid carrier or both, and then, if necessary, the product is molded into a desired preparation to prepare the preparation.
[0060] The formulations suitable for oral administration of the present application can be provided in discrete units, such as capsules, cachets or tablets, each containing a predetermined amount of active ingredient; powder or granules; solution or suspension in an aqueous liquid or a non-aqueous liquid; or an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient can also be provided in the form of a pill, suppository or paste.
[0061] Tablets can be made by compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing the active ingredient in free-flowing form, such as powder or granules, in a suitable machine, optionally mixed with a binder, lubricant, inert diluent, lubricant, surfactant or dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. Tablets can be optionally coated or scored, and can be formulated to provide sustained release, delayed release or controlled release of the active ingredient therein.
[0062] Preparations for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, antibacterial agents and solutes to keep the preparation isotonic with the blood of the intended recipient. Preparations for parenteral administration also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. The above preparations can be provided in unit doses of multiple dose containers, such as sealed ampoules and vials, and can be stored in freeze-dried (lyophilized) conditions, only requiring the addition of sterile liquid carriers, such as saline, phosphate buffered saline (PBS) immediately before use. Emergency injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the aforementioned types.
[0063] It will be appreciated that the compounds of the present invention may exist in radiolabeled form, i.e., the compounds may contain one or more atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Radioactive isotopes of hydrogen, carbon, phosphorus, fluorine and chlorine include 2 H. 3 H. 13 C. 14 C. 15 N. 35 S. 18 F and 36 Compounds containing these radioactive isotopes and / or other radioactive isotopes of other atoms are within the scope of this application. Tritium (i.e. 3 H) and carbon-14 (i.e. 14 C), is particularly preferred due to its ease of preparation and detectability. 11 C. 13 N. 15 O and 18The compound of F is very suitable for positron emission computed tomography. The radiolabeled compounds of Formula I, II and III of the present application and their prodrugs can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by the methods disclosed in the following examples and schemes by replacing non-radiolabeled reagents with readily available radiolabeled reagents.
[0064] The compounds provided herein are useful for treating a neurodegenerative disease in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I, II, or III.
[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. A complete list of abbreviations used by organic chemists (i.e., those of ordinary skill in the art) appears in the Journal of Organic Chemistry 》in the first issue of each volume. This list is generally presented in a table entitled "Standard List of Abbreviations", which is incorporated herein by reference. If there is more than one definition for a term referenced herein, the definition in this section shall prevail unless otherwise indicated.
[0066] As used herein, the term "comprising" or its grammatical variations will be considered to specify the stated features, integers, steps or components, but does not exclude the addition of one or more additional features, integers, steps, components or groups. The term includes the terms "consisting of" and "consisting essentially of.
[0067] When used herein, the phrase "consisting essentially of" or its grammatical variations should be considered to specify the stated features, integers, steps, or components, but not to exclude the addition of one or more additional features, integers, steps, components, or combinations thereof (only when the additional features, integers, steps, components, or combinations thereof do not materially alter the basic and novel characteristics of the claimed composition or method).
[0068] As used herein, "patient" includes humans and other animals, particularly mammals. Therefore, the method is suitable for human treatment and veterinary applications. In some embodiments, the patient is a mammal, such as a primate. In some embodiments, the patient is a human.
[0069] Treatment may include administering the compounds described herein to a patient diagnosed with a disease, and may include administering the compounds to a patient without effective symptoms. Conversely, treatment may include administering the compositions to a patient at risk of developing a particular disease, or to a patient suffering from one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have been made.
[0070] The term "administering" about the dosage form of the present application refers to the behavior of introducing the dosage form into the subject system in need of treatment. When the dosage form of the present application is given in combination with one or more other activating agents (in their respective dosage forms), "administering" and its variants are understood to include introducing the dosage form and another activating agent simultaneously and / or sequentially. The administration of any of the dosage forms includes parallel administration, co-administration or sequential administration. In some cases, these treatment methods are implemented at approximately the same time, for example, differing from each other by approximately a few seconds to a few hours.
[0071] A "therapeutically effective" amount of a compound described herein is generally an amount sufficient to achieve the desired effect, and may vary depending on the nature and severity of the disease condition and the potency of the compound. It should be understood that different concentrations may be used for prevention than for treatment of active disease. A therapeutic benefit is obtained by alleviating one or more of the physiological symptoms associated with the underlying disease, such that an improvement in the condition is observed, although the patient may still suffer from the underlying disease.
[0072] Throughout the specification, terms and substituents retain their definitions.
[0073] C1-C 20 Hydrocarbons include alkyl, cycloalkyl, polycycloalkyl, alkenyl, alkynyl, aryl, and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, adamantyl, camphoryl, and naphthylethyl. Hydrocarbon refers to any substituent consisting of hydrogen and carbon as the only two elements. Aliphatic hydrocarbons are hydrocarbons without aromaticity; they may be saturated or unsaturated, cyclic, straight-chain or branched. Examples of aliphatic hydrocarbons include isopropyl, 2-butenyl, 2-butynyl, cyclopentyl, norbornyl, and the like. Aromatic hydrocarbons include benzene (phenyl), naphthalene (naphthyl), anthracene, and the like.
[0074] Unless otherwise specified, alkyl (or alkylene) is intended to include straight or branched saturated hydrocarbon structures and combinations thereof. Alkyl refers to an alkyl group comprising 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, and the like.
[0075] Cycloalkyl is a subset of hydrocarbons, including cyclic hydrocarbon groups of 3 to 8 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, norbornyl, and the like.
[0076] Unless otherwise indicated, the term "carbocycle" is intended to include ring systems in which the ring atoms are all carbon, but not in any oxidation state. Thus, (C3-C 10 )Carbocyclic ring refers to non-aromatic systems and aromatic systems, including cyclopropane, benzene and cyclohexene systems; (C8-C 12)Carbocyclic refers to systems such as norbornane, decalin, indane dioxide and naphthalene. Unless otherwise specified, carbocyclic refers to monocyclic, bicyclic and polycyclic rings.
[0077] Heterocycle refers to an aliphatic or aromatic carbocyclic residue wherein 1-4 carbon atoms are selected from heteroatoms comprising N, O and S. The heteroatoms of nitrogen and sulfur may be optionally oxidized, and the nitrogen heteroatoms may be optionally quaternized. Unless otherwise indicated, heterocycle may be non-aromatic (heteroaliphatic) or aromatic (heteroaryl). Examples of heterocycles include pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxane, benzodioxole (when appearing as a substituent, commonly referred to as methylenedioxyphenyl), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran, etc. Examples of heterocyclyl residues include piperazinyl, piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, thienyl (historically also known as phenylthio), benzothienyl, thiamorpholinyl, oxadiazolyl, triazolyl and tetrahydroquinolinyl.
[0078] Hydrocarbyloxy or alkoxy refers to a group of straight or branched configuration having 1-20 carbon atoms (preferably 1-10 carbon atoms, more preferably 1-6 carbon atoms) connected to the parent structure through oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, etc. Lower alkoxy refers to a group containing 1-4 carbons. For the present application, alkoxy and lower alkoxy include methylenedioxy and ethylenedioxy.
[0079] Oxaalkyl refers to an alkyl residue in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9-trioxadecanyl, etc. The term "oxaalkyl" is as understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, 196, published by the American Chemical Society, but not limited by 127 (a)], that is, it refers to a compound in which oxygen is bound to its adjacent atoms by a single bond (forming an ether bond); it does not refer to a double-bonded oxygen as found in a carbonyl group. Similarly, thioalkyl and azaalkyl refer to an alkyl residue in which one or more carbons are replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
[0080] The term "halogen" refers to a fluorine, chlorine, bromine or iodine atom. In one embodiment, the halogen can be a fluorine or chlorine atom.
[0081] Unless otherwise indicated, acyl refers to formyl, as well as straight chain, branched, cyclic configurations, saturated, unsaturated and aromatic groups and combinations thereof having 1, 2, 3, 4, 5, 6, 7 and 8 carbon atoms connected to the parent structure through a carbonyl functional group. Examples include acetyl, benzoyl, propionyl, isobutyryl, etc. Lower acyl refers to groups containing 1-4 carbons. When the double bonded oxygen itself is referred to as a substituent, it is referred to as "oxo".
[0082] As used herein, the term "optionally substituted" can be used interchangeably with "unsubstituted or substituted". The term "substituted" refers to the replacement of one or more hydrogen atoms in a specific group with a specific group. For example, substituted alkyl, aryl, cycloalkyl, heterocyclyl, etc. refer to such alkyl, aryl, cycloalkyl or heterocyclyl groups, wherein one or more H atoms in each residue are replaced by the following groups: halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxy lower alkyl, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, lower alkoxy, haloalkoxy, oxaalkyl, carboxyl, alkoxycarbonyl [-C (=O) O-alkyl], alkoxycarbonylamino [HNC (=O) O-alkyl], aminocarbonyl (also known as carboxamido) [-C (=O) NH2], alkylaminocarbonyl [-C (=O) NH-
[0063] The term "alkyl" refers to any of the following groups: alkyl], cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, (alkyl)(aryl)aminoalkyl, alkylaminoalkyl (including cycloalkylaminoalkyl), dialkylaminoalkyl, dialkylaminoalkoxy, heterocyclylalkoxy, sulfhydryl, alkylthio, sulfoxide, sulfone, sulfonamido, alkylsulfinyl, alkylsulfonyl, amidoalkyl, amidoalkoxy, amido, amidino, aryl, benzyl, heterocyclyl, heterocyclylalkyl, phenoxy, benzyloxy, heteroaryloxy, hydroxyimino, alkoxyimino, oxaalkyl, sulfonamide, trityl, amidino, guanidino, urea, benzyloxyphenyl and benzyloxy. "Oxo" is also included in the substituent referred to by "optionally substituted"; those skilled in the art will understand that since oxo is a divalent group, there will be cases where it is not suitable as a substituent (e.g., on phenyl). In one embodiment, 1, 2 or 3 hydrogen atoms are substituted by specific groups. In the case of alkyl and cycloalkyl groups, more than three hydrogen atoms may be replaced by fluorine; in fact, all available hydrogen atoms may be replaced by fluorine.
[0083] Substituent R n The definitions are generally defined upon introduction and are maintained throughout the specification and all independent claims. For compounds shown or claimed for any and all possible tautomers, it is intended that all possible tautomers are included. Experimental Section
[0084] Preparation compound may involve the protection and deprotection of various chemical groups. Those skilled in the art can easily determine whether to need protection and deprotection and select suitable blocking groups. Suitable groups suitable for this purpose are discussed in the standard textbooks of chemical field, for example, in " organic synthesis blocking groups " (Protective Group in Organic Synthesis) (John Wiley & Sons, New York, 1999) of TW Greene and PGM Wuts, in " chemical blocking groups " (Protecting Group in Chemistry, the 1st edition, Oxford University Press, 2000), and in " March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure " (March's Advanced Organic Chemistry:Reactions, Mechanisms, and Structure, the 5th edition, Wiley-Interscience publishes, 2001) all have discussion.
[0085] Benzimidazole compounds can be synthesized by any of the following methods: i) reacting an optionally substituted 2-nitroaniline with an aromatic aldehyde in the presence of sodium bisulfite (D. Fokas et al., Synthesis 2005, 1, 47-56); ii) reacting an acid chloride with an optionally substituted 1,2-phenylenediamine, followed by condensation of the intermediate amide ring. Method A-2-Nitroaniline reacts with aromatic aldehydes to form benzimidazoles Example 1: 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole A solution of 2-nitroaniline (691 mg, 5.00 mmol) and 4-tert-butylbenzaldehyde (836 μL, 5.00 mmol, 1.0 equiv) in ethanol (20 mL) was treated with a freshly prepared 1 M aqueous sodium bisulfite solution (15 mL, 15.0 mmol, 3.0 equiv) and the mixture was heated at 70 ° C for 14 hours. The mixture was cooled to ambient temperature, quenched by adding a 5 M aqueous ammonium hydroxide solution (10 mL), and the solid formed was collected by filtration and washed several times with water. The product was purified by recrystallization from ethanol-water to give an off-white solid (739 mg, 59%). 1H NMR (500MHz, DMSO-d6): δ12.84 (1H, br s), 8.10 (2H, d, J = 8.4Hz), 7.57 (4H, app d, J = 8.4Hz, overlapping br), 7.21-7.17 (2H, m), 1.33 (9H, s); LCMS: rt 2.48-2.52min,+ve ESI m / z 250.8([M+H] + ,100%),-ve ESI m / z 248.7(M–H] - ,100%). Method B: The acyl chloride reacts with 1,2-phenylenediamine and then undergoes a ring condensation reaction of the intermediate amide to generate a benzimidazole compound. Example 2: 2-(4-(tert-butyl)phenyl)-1H-imidazo[4,5-c]pyridine 4-tert-butylbenzoyl chloride (781 μL, 4.00mmol, 1.0 equivalent) in DMF (1mL) was added dropwise to a cooling (0 ° C) solution of 3,4-diaminopyridine (437mg, 4.00mmol) and triethylamine (669 μL, 4.80mmol, 1.2 equivalent) in dimethylformamide (DMF) (15mL). The mixture was allowed to warm to ambient temperature and stirred for 12 hours. The mixture was slowly added to vigorously stirred ice water (240mL), and the solid formed was collected by filtration. Purification by flash chromatography (hexane-EtOAc, 100:0 to 0:100) gave N-(4-aminopyridin-3-yl)-4-(tert-butyl)benzamide (369mg, 34%) as a white solid. 1 HNMR (500MHz, DMSO-d6): δ9.66 (1H, s), 8.09 (1H, s), 7.89 (2H, d, J = 8.4Hz), 7.80 (1H, d, J = 5.2Hz), 7.55(2H,d,J=8.4Hz),7.44(1H,d,J=5.2Hz),5.17(2H,s),1.32(9H,s);LCMS:rt2.46-2.50min,+ve ESI m / z 269.7([M+H] + ,100%),-ve ESI m / z 267.7(M–H] - ,100%). A solution of N-(4-aminopyridin-3-yl)-4-(tert-butyl)benzamide (135 mg, 0.50 mmol) in glacial acetic acid (5 mL) was heated at 70 °C for 14 h. The solution was cooled to ambient temperature and poured into ethyl acetate (50 mL). The organic layer was washed with water (2 x 5 mL), saturated aqueous sodium bicarbonate solution (2 x 5 mL), brine (5 mL), dried (Na2SO4), and the solvent was evaporated under reduced pressure. The residue was resuspended in a small amount of ethyl acetate (~0.5 mL) and treated dropwise with hexane under stirring. The precipitate formed was filtered and dried to give 2-(4-(tert-butyl)phenyl)-1H-imidazole[4,5-c]pyridine (34 mg, 27%) as a white solid. 1 H NMR (500MHz, CD3OD): δ8.88 (1H, s), 8.32 (1H, d, J = 5.6Hz), 8.09 (2H, d, J = 8.4Hz), 7.64 (3H, app d, J = 8.4Hz, overlapping), 1.39 (9H, s); LCMS: rt 2.41-2.45min, +ve ESI m / z 251.8([M+H] + ,100%),-ve ESI m / z 249.7(M–H] - ,100%).
[0086] The optionally substituted 2-aminothiophenol is reacted with an acyl chloride and then heated to synthesize a benzothiazole compound. Method C - Reaction of acyl chloride with 2-aminothiophenol to form a benzothiazole compound Example 3: 2-(4-tert-butylphenyl)-1,3-benzothiazole To 2-aminothiophenol (1.070mL, 10mmol) solution in NMP (20mL) was added 4-tert-butylbenzoyl chloride (2.930mL, 15mmol, 1.5 equivalents), and the solution was heated to 100°C for 6 hours. The cooled reactant was poured into ice water (300mL), and the pH was adjusted to 9-10 by adding concentrated NH4OH aqueous solution. The mixture was filtered and washed with water several times. Purified by flash chromatography (hexane-EtOAc, 100:0 to 70:30) to give a white crystalline solid (1.831g, 65%). 1HNMR (500MHz, CDCl3): δ8.07(1H,d,J=8.1Hz), 8.03(2H,d,J=8.4Hz), 7.90(1H,d,J=8.1Hz), 7.52 (2H,d,J=8.4Hz),7.49(1H,td,J=7.8,0.8Hz),7.37(1H,td,J=7.8,0.8Hz),1.37(9H,s); LCMS:rt 4.58-4.62min,+ve ESI m / z 268.1([M+H] + ,100%).
[0087] Optionally substituted 2-aminophenol is reacted with an acyl chloride and then heated to synthesize benzoxazole compounds. Methods D-acyl chloride reacts with 2-aminophenol to form benzoxazole Example 4: 2-(4-tert-butylphenyl)-1,3-benzoxazole To a cooled (0°C) solution of 2-aminophenol (1.091 mL, 10 mmol) in NMP (5 mL) was added 4-tert-butylbenzoyl chloride (1.953 mL, 10 mmol, 1.0 eq) dropwise, followed by pyridine (1.011 mL, 12.5 mmol, 1.25 eq) and the solution was stirred at 180°C for 3 hours. The reaction was poured into water-MeOH (80:20, 20 mL) and the mixture was cooled to 0°C. The precipitated product was filtered and purified by flash chromatography (hexane-EtOAc, 100:0 to 75:25) to give a white solid (1.977 g, 75%). 1 H NMR (500MHz, CDCl3): δ8.19(2H,d,J=8.5Hz),7.79-7.75(1H,m),7.59-7.57(1H,m),7.55(2H,d,J=8.5Hz),7.36-7.33(2H,m),1.38(9H,s); LCMS:rt 4.38-4.42min,+ve ESI m / z 252.1([M+H] + ,100%).
[0088] Imidazolo[1,2-a]pyridine is synthesized by heating 2-aminopyridine with 2-bromo-1-phenylethanol-1-one in the presence of a base. Method E - Reaction of 2-aminopyridine with 2-bromo-1-phenylethanol-1-one to form imidazo[1,2-a]pyridine Example 5: 2-(4-tert-butylphenyl)imidazo[1,2-a]pyridine Pyridine-2-amine (63.8mg, 0.68mmol) and 2-bromo-1-(4-tert-butylphenyl)ethanone (0.136mL, 0.68mmol) are added to a flask and dissolved in acetonitrile (2.7mL), followed by the addition of sodium bicarbonate (114mg, 1.36mmol). The reactant is refluxed for 1 hour and then cooled. The precipitate is removed by filtration, and the filtrate is evaporated under reduced pressure. The crude product is purified by flash chromatography (50:50EtOAC:hexane) to give a yellow solid 2-(4-tert-butylphenyl)imidazo[1,2-a]pyridine (0.061g, 35%). 1 H NMR (500MHz, CD3OD): δ8.42(1H,d,J=6.9Hz),8.16(1H,s),7.85(2H,d,J=8.4Hz),7.55(1H,d,J=9 .1Hz), 7.49 (2H, d, J = 8.4Hz), 7.32 (1H, t, J = 7.9Hz), 6.92 (1H, t, J = 6.8Hz), 1.36 (9H, s); LCMS: rt 2.51-2.55min,+ve ESI m / z 250.8([M+H] + ,100%). Method F-Alkylation of benzimidazoles to obtain 1-alkyl-benzimidazoles
[0089] 1-Alkyl-benzimidazole is synthesized by dropwise addition of alkyl halide in the presence of sodium bicarbonate or sodium carbonate. Example 6: 2-(4-tert-Butylphenyl)-1-methyl-benzo[d]imidazole White solid. 1 H NMR (500MHz, CD3OD): δ7.73(2H,d,J=8.4Hz), 7.68(1H,d,J=7.9Hz), 7.65(2H,d,J=8.4Hz), 7.55( 1H,d,J=7.9Hz),7.35(1H,t,J=7.8Hz),7.31(1H,t,J=7.8Hz),3.90(3H,s),1.40(9H,s); LCMS:rt 2.63-2.67min,+ve ESI m / z 264.8([M+H] + ,100%).
[0090] Table 1 shows the compound names, structures, spectral data and synthesis methods (SM) of Examples 7-78. Table 1
[0091] The benzimidazole prodrugs were synthesized by Method G and Method H described below. Method G-Reaction of halomethyl esters and halomethyl carbonates to generate benzimidazole prodrugs
[0092] The benzimidazole prodrugs were prepared by heating the benzimidazole with a chloromethyl ester in the presence of sodium iodide and sodium carbonate at refluxing acetone; alternatively, the benzimidazole prodrugs could be prepared by heating the benzimidazole with chloromethyl carbonate in the presence of sodium iodide and sodium carbonate at refluxing acetone (Examples 6-P to 9-P and 11-P).
[0093] In a typical procedure described below, a solution of benzimidazole (1.0 mmol) in acetone (10 mL) was treated with sodium carbonate (2.0-3.0 mmol), sodium iodide (1.0-1.5 mmol) and optionally protected chloromethyl ester (1.0-1.5 mmol). The mixture was heated at reflux until the reaction was complete. The mixture was then filtered and the solvent was evaporated and then purified using silica gel flash chromatography. The deprotection of the product was completed using standard protocols known in the art (Examples 10-P and 12-P).
[0094] Alternatively, treatment of the benzimidazole with sodium hydride followed by addition of the bromomethyl ester affords the desired prodrug (Example 5-P). Example 1-P: Methyl (2-4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)acetate A cooled (0°C) solution of 2-(4-tert-butylphenyl)-1H-benzimidazole (250 mg, 1.00 mmol) in DMF (5 mL) was treated with sodium hydride (60% dispersion in mineral oil, 40 mg, 1.00 mmol, 1.0 eq) in batches and stirred at ambient temperature for 1 hour. The mixture was cooled to 0°C, bromomethyl acetate (98 uL, 1.00 mmol, 1.0 eq) was added dropwise, and stirred at ambient temperature for 48 hours. The reactants were poured into water (100 mL) and extracted with EtOAc (4×25 mL). The combined organic layers were washed with brine (25 mL), dried (Na2SO4), and the solvent was evaporated under reduced pressure. The crude residue was purified by flash chromatography on silica gel, eluting with hexane-EtOAc (100:0 to 60:40) to give the title compound as a white crystalline solid (108 mg, 32%). 1 H NMR (500MHz, CDCl3): δ7.83-7.81(1H,m),7.80(2H,d,J=8.4Hz),7.62-7.60(1H,m),7. 57(2H,d,J=8.4Hz),7.36-7.33(2H,m),6.18(2H,s),2.18(3H,s),1.38(9H,s).LCMS:rt 3.27-3.47min,+ve ESI m / z322.8([M+H] + ,100%). Example 2-P: Methyl (2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)butanoate By 2- (4- tert-butylphenyl) -1H- benzimidazole (501mg, 2.00mmol), sodium carbonate (636mg, 6.00mmol, 3.0 equivalents) in acetone (20mL) mixture with chloromethyl butyrate (382 μ L, 3.00mmol, 1.5 equivalents), and the mixture is heated to reflux 24 hours. The mixture is cooled to ambient temperature, filtered, and the solvent is evaporated under reduced pressure. By flash chromatography residue (hexane-EtOAc, 100: 0 to 70: 30), waxy solid is obtained, ground with hexane, and white solid (143mg, 20%) is obtained. 1H NMR (500MHz, CDCl3): δ7.83-7.81(1H,m),7.80(2H,d,J=8.4Hz),7.62-7.60(1H,m),7.56(2H,d,J=8.4Hz),7.35-7.33(2H,m),6.18( 2H,s),2.41(2H,t,J=7.4Hz),1.74-1.67(2H,app.sextet,J=7.4Hz),1.38(9H,s),0.96(3H,t,J=7.4Hz); LCMS:rt3.62-3.78min,+ve ESI m / z 350.9([M+H] + ,100%). Example 3-P: Methyl (2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)isobutyrate The mixture of 2-(4-tert-butylphenyl)-1H-benzimidazole (501mg, 2.00mmol), sodium carbonate (636mg, 6.00mmol, 3.0 equivalents) and sodium iodide (450mg, 3.00mmol, 1.5 equivalents) in acetone (20mL) was treated with methyl 2-methylpropanoate (379 μL, 3.00mmol, 1.5 equivalents), and the mixture was heated to reflux for 24 hours. The mixture was cooled to ambient temperature, filtered and the solvent was evaporated under reduced pressure. By flash chromatography purification of residue (hexane-EtOAc, 100:0 to 70:30), a waxy solid was obtained, which was ground with hexane to obtain a white solid. Example 4-P: (2-(4-(tert-butylphenyl)-1H-benzo [d] imidazole-1-yl) methyl pivalate A mixture of 2-(4-tert-butylphenyl)-1H-benzimidazole (250 mg, 1.00 mmol), sodium carbonate (159 mg, 1.50 mmol, 1.5 equivalents) and sodium iodide (165 mg, 1.10 mmol, 1.1 equivalents) in acetone (10 mL) was treated with chloromethyl pivalate (159 μL, 1.10 mmol, 1.1 equivalents) and the mixture was heated at reflux for 24 hours. The mixture was cooled to ambient temperature, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (hexane-EtOAc, 100: 0 to 70: 30) to give a white solid (41 mg, 11%). LCMS: rt 3.87-3.91 min, +ve ESI m / z 364.9 ([M+H] + ,100%). Example 5-P: tert-Butyl ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl)succinate A mixture of 2-(4-tert-butylphenyl)-1H-benzimidazole (1001 mg, 4.00 mmol), sodium carbonate (848 mg, 8.00 mmol, 2.0 equiv) and sodium iodide (660 mg, 4.40 mmol, 1.1 equiv) in acetone (40 mL) was treated with tert-butyl chloromethyl succinate (ClCH2OC(=O)CH2CH2C(=O)OC(CH3)3) (980 mg, 4.40 mmol, 1.1 equiv) and the mixture was heated at reflux for 48 hours. The mixture was cooled to ambient temperature, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (hexane-EtOAc, 100:0 to 70:30) to give a waxy solid, which was triturated with hexane to give a white solid (487 mg, 28%). 1 H NMR (500MHz, CDCl3): δ7.83-7.80(3H,m,overlapping),7.61-7.59(1H,m),7.57(2H,d,J=8.4Hz),7.35-7 .33(2H,m),6.20(2H,s),2.69(2H,t,J=6.5Hz),2.60(2H,t,J=6.5Hz),1.41(9H,s),1.38(9H,s); LCMS:rt 3.80-3.90min,+ve ESI m / z 437.1([M+H] + ,100%). Example 6-P: 4-((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methoxy)-4-oxobutanoic acid Tert-butyl ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl)succinate (Example 9-P, 87 mg, 0.200 mmol) in dichloromethane (0.5 mL) was treated with trifluoroacetic acid (0.5 mL) and the solution was stirred at ambient temperature for 4 hours. The solution was evaporated under reduced pressure and dried under high vacuum to give a white crystalline solid (70 mg, 92%). 1H NMR (500MHz, CDCl3): δ8.02(1H,m),7.92(2H,d,J=8.1Hz),7.86-7.84(1H,m),7.71(2H,d,J=8.1Hz),7.61-7.60(2H,m),6.32(2H,s),6.01(1H,br s),2.73(4H,s),1.39(9H,s).LCMS:rt 2.90-2.94min,+ve ESI m / z 380.9([M+H] + ,100%). Example 7-P: (2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl 4-(((tert-butoxycarbonyl)amino)methyl)benzoate A mixture of 2-(4-tert-butylphenyl)-1H-benzimidazole (1001 mg, 4.00 mmol), sodium carbonate (1272 mg, 12.00 mmol, 3.0 equivalents) and sodium iodide (660 mg, 4.40 mmol, 1.1 equivalents) in acetone (40 mL) was treated with 4-(((tert-butoxycarbonyl)amino)methyl)benzoate (1319 mg, 4.40 mmol, 1.1 equivalents), and the mixture was heated to reflux for 48 hours. The mixture was cooled to ambient temperature, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (hexane-EtOAc, 100:0 to 70:30) to give a white solid (532 mg, 26%). 1 H NMR (500MHz, CDCl3): δ8.04 (2H, d, J = 8.3Hz), 7.87-7.83 (3H, m, overlapping), 7.68-7.66 (1H,m),7.58(2H,d,J=8.3Hz),7.39-7.34(4H,m,overlapping),6.43(2H,s),4.93(1H,br s), 4.38 (2H, d, J = 5.2Hz), 1.46 (9H, s), 1.38 (9H, s); LCMS: rt 3.88-3.92min, +ve ESI m / z 514.1 ([M+H] + ,100%). Example 8-P: (4-(((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methoxy)carbonyl)-phenyl)methanamine hydrochloride A solution of (2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl 4-(((tert-butoxycarbonyl)amino)methyl)benzoate (462 mg, 0.90 mmol) in ethyl acetate (13.5 mL) was treated with a 2.5 M solution of hydrogen chloride in ethanol (3.6 mL, 9.00 mmol, 10.0 equiv) and the solution was stirred at ambient temperature for 24 hours. The solution was evaporated under reduced pressure and dried under vacuum. The solid obtained was recrystallized from methanol-ether to give fine white needles (337 mg, 93%). 1 H NMR (500MHz, CD3OD): δ8.24-8.22(1H,m),8.14(2H,d,J=8.3Hz),8.01-7.99(2H,m),7.90-7.87 (3H,m),7.76-7.70(2H,m),7.63-7.60(2H,m),6.69(2H,s),4.21(2H,s),1.45(9H,s).LCMS:rt 2.66-2.70min,+ve ESI m / z 414.0([M+H] + , 20%). Method H-Reaction with dialkyl chloromethyl phosphate to form benzimidazole prodrug
[0095] The benzimidazole prodrug is prepared by treating the benzimidazole with an excess of sodium hydride and then treating it with dialkyl chloromethyl phosphate. In the case of di-tert-butyl chloromethyl phosphate, the resulting product can be subjected to acid-mediated hydrolysis to obtain the dihydrogen phosphate prodrug. The method is adapted from the methods reported by Chassaing et al. (J Med Chem. 2008, 51, 1111) and Flores-Ramos et al. (Bioorg Med Chem Lett. 2014, 24, 5814). Example 9-P: Di-tert-butyl ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl) phosphate To a cooled (0°C) solution of 2-(4-tert-butylphenyl)-1H-benzimidazole (2.00 g, 8.00 mmol) in DMF (35 mL) was added sodium hydride (60% dispersion in oil, 1.12 g, 28.0 mmol, 3.5 eq) portionwise and the mixture was stirred at ambient temperature for 1 h. The mixture was cooled (0°C) and a solution of di-tert-butyl chloromethyl phosphate (2.41 mL, 10.4 mmol, 1.3 eq) in DMF (5 mL) was added dropwise and stirred at ambient temperature for 12 h. The mixture was cooled (0°C), diluted with DCM (150 mL) and carefully added dropwise and then treated with water (50 mL) portionwise. The layers were separated and the organic layer was washed with water (3 x 50 mL), brine (2 x 50 mL), dried (Na2SO4) and the solvent evaporated. The crude product was purified by flash chromatography on silica gel (hexanes-EtOAc, 100:0 to 50:50) and the resulting oil crystallized overnight at -20° C. The crystalline material was triturated with hexanes (3×10 mL) to give a white solid (2.54 g, 64%). 1 H NMR (500MHz, CDCl3): δ7.87(2H,d,J=8.4Hz),7.82-7.80(1H,m),7.76-7.74(1H,m),7.56(2H ,d,J=8.4Hz),7.36-7.32(2H,m),6.00(2H,d,J=8.2Hz),1.43(18H,s),1.38(9H,s); LCMS:rt 3.7-3.8min,+ve ESI m / z 473.0([M+H] + ,100%). Example 10-P: Dihydrogen ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl)phosphate To a solution of di-tert-butyl ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl) phosphate (118 mg, 0.25 mmol) in 1,4-dioxane (0.5 mL) was added dropwise to a 4M solution of hydrogen chloride in 1,4-dioxane (0.5 mL) at room temperature, and the mixture was stirred for 20 hours. The reaction mixture was diluted with 1,4-dioxane (0.5 mL), and the precipitate was filtered, washed with cold dioxane (1.0 mL), cold diethyl ether (1.0 mL), and dried under high vacuum to give white crystals (69 mg, 73%). 1H NMR (500MHz, DMSO-d6): δ8.04(1H,d,J=7.9Hz), 7.96(2H,d,J=8.4Hz), 7.87(1H,d,J=7.9H z),7.76(2H,d,J=8.4Hz),7.62-7.56(2H,m),6.05(2H,d,J=9.0Hz),1.37(9H,s); LCMS:rt 2.1-2.2min,+ve ESI m / z360.8([M+H] + ,100%),-ve ESI m / z358.7([MH] - ,100%). Example 11-P: Disodium ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl]methyl)phosphate To a suspension of ((2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl)dihydrogen phosphate (180 mg, 0.500 mmol) in methanol (5 mL) was added dropwise to a 0.5 M solution of sodium methoxide in methanol (2 mL, 1.00 mmol, 2.0 equiv) at ambient temperature. The resulting clear solution was evaporated under reduced pressure and dried under high vacuum to give a white solid (196 mg, 96%). 1 H NMR(500MHz,D2O): δ7.92-7.89(3H,m,overlapping),7.79-7.77(3H,m,overlapping),7 .50(1H,t,J=7.5Hz),7.46(1H,t,J=7.5Hz),5.88(2H,d,J=4.3Hz),1.40(9H,s);LCMS:rt 2.06-2.10min,+ve ESI m / z 360.8([M+H] + ,100%),-ve ESI m / z 358.7([MH] - ,100%).
[0096] Other prodrug derivatives synthesized are shown below. Examples of carbamates are generally formed by treating the benzimidazole precursor with the appropriate chloroformate in pyridine / dichloromethane. Example 12-P: (2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)methyl(tert-butoxycarbonyl)-L-alaninate Example 13-P: Ethyl 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole-1-carboxylate Example 14-P: Methyl 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole-1-carboxylate Example 15-P: Ethyl 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole-1-carboxylate Example 16-P: Propyl 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole-1-carboxylate Example 17-P: 1-(2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazol-1-yl)ethan-1-one Bioassay
[0097] Oxidative metabolism exerts an anti-inflammatory effect on the myeloid cell phenotype (O'Neill LA, Front Immunol. 2014), and Ppargc1a can promote this energy metabolism pathway (Spiegelman BM, Novartis Found Symp. 2007). Therefore, it can be expected that pharmacological activation of Ppargc1a will inhibit the inflammatory response of myeloid cells. This phenomenon can be measured in culture by TNF-α inhibition assay. Cell-based assay to measure TNF-α inhibition Mouse bone marrow cells BV2 or human peripheral blood mononuclear cells (PBMC) were cultured in RPMI 1640 medium (Cat#11875119, Gibco) supplemented with 10% fetal bovine serum and 1% L-glutamine 1% penicillin. These cells were then stimulated with 100 ng / ml lipopolysaccharide (LPS, O111:B4, Cat#L2630, Sigma) for 24 hours. LPS stimulation resulted in the secretion of inflammatory cytokine TNF-α by BV2 cells or PBMC, which can be quantified by ELISA according to the manufacturer's method (Cat#558273 for BV2 and Cat#558299 for PBMC, BD Biosciences). In order to determine whether the exemplary compound 1-78 inhibits the production of TNF-α by BV2 cells or PBMC, cells were cultured in the presence of different concentrations of the compound, and the reduction ratio of the production of TNF-α relative to the production of TNF-α in the same cells cultured in the presence of dimethyl sulfoxide (as a vehicle control) was determined. The results are shown in Table 2. Table 2 - TNF-inhibitory effects
[0098] The selected compounds of the present application were subjected to microsomal stability test and Caco-2 permeability test. Microsome stability test method Human liver microsomes (Corning #452117 batch 38291) or mouse liver microsomes (Corning #452701 batch 6328004) were mixed with KxPO4 pH 7.4 (100mM), MgCl2 (10mM) and the test compound (1μM) at a final concentration of 11.25mg protein / compound and pre-incubated (10 minutes, 37°C). Next, NADPH (1mM) was added to start the reaction (total volume 100μL). At various time points (0, 10, 20 and 40 minutes), the reaction was quenched with Clem stop solution (100μL, 625ng / mL) (Cyprotex) in acetonitrile. The samples were centrifuged at 4000g for 20 minutes, diluted (75μL was dissolved in 75μL of 0.1% formic acid in water), and analyzed by LC-MS / MS. The results are shown in Table 3. Caco-2 permeability test method Caco-2 cells were maintained in DMEM under 5% CO2 atmosphere. For transport experiments, 5 × 10 5 Cells / well were seeded on polycarbonate filter pads and allowed to grow and differentiate for 21 ± 4 days before the cell monolayers were used for the experiments. The apparent permeability coefficients in the A→B and B→A directions were determined in the presence and absence of elacridar as a transporter inhibitor. Up to three test items and reference compounds were dissolved in Hank's balanced salt solution, pH 7.4, at a final concentration of 10 μM. The assay was performed at 37°C in HBSS containing 25 mM HEPES (pH 7.4). Prior to the study, the monolayers were washed in pre-warmed HBSS. At the start of the experiment, pre-warmed HBSS containing the test item was added to the donor side of the monolayer and HBSS without the test item was added to the receiver side. Aliquots of the receiver side were taken during the 2-hour incubation period; aliquots of the donor side were taken at 0 and 2 hours. The aliquots were diluted with an equal volume of methanol / water and 0.1% formic acid containing an internal standard. The mixtures were analyzed by LC-MS / MS. The apparent permeability coefficient (Papp) is calculated using the following formula: app =(dC rec / dt) / (A×C 0,donor )]×106, where dC rev / dt is the change in concentration in the receiver compartment over time, C 0,donoris the concentration in the donor compartment at 0, and A is the area of cells in the compartment. The results are shown in Table 3. Table 3 - Microsomal stability and Caco-2 permeability
[0099] Pharmacokinetic studies (mice) were conducted on Example 1, 6-P, 8-P and 11-P compounds of the present application. The dose of Example 1, 6-P, 8-P and 11-P compounds in mice was 10 mg / kg p.o. (n=2). Plasma, brain tissue and liver samples were taken at 0.5 hours, 1 hour, 2 hours and 4 hours. The samples were analyzed by LCMS to determine the level of Example 1 compound, i.e., the active pharmaceutical ingredient (API) of the prodrug Examples 6-P, 8-P and 11-P.
[0100] Figure 1 Plasma API levels are shown for prodrug examples 6-P, 8-P and 11-P.
[0101] Figure 2 Brain tissue API levels are shown for prodrug examples 6-P, 8-P, and 11-P.
[0102] Figure 3 Liver API levels are shown for prodrug examples 6-P, 8-P, and 11-P.
[0103] Generally speaking, Figure 1-3 Prodrug examples 6-P, 8-P and 11-P were shown to result in measurable levels of API in plasma, brain tissue and liver in a mouse PK study.
[0104] Although typical embodiments have been proposed for illustrative purposes, the above description and examples should not be considered to limit the scope of the present application. Therefore, various modifications, changes and substitutions may occur to those skilled in the art without departing from the spirit and scope of the present application.
Claims
1. A pharmaceutical composition comprising a compound of the following formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is suitable for oral or parenteral administration.
2. The pharmaceutical composition of claim 1, wherein the carrier is suitable for oral administration.
3. The pharmaceutical composition of claim 1, wherein the carrier is suitable for parenteral administration.
